

# ESMO ADVANCED COURSE PROGRAMME

## ER+/HER2- Advanced Breast Cancer: Defining Endocrine Sensitivity & Optimizing Therapeutic Sequencing Post-CDK4/6 Inhibitors

Jeddah, Saudi Arabia  
6 September 2025

---

**CO-CHAIRS** Meteb Al-Foheidi, Saudi Arabia  
Barbara Pistilli, France

**MODERATORS** Ahmed Alwbari, Saudi Arabia  
Ahmed Alshehri, Saudi Arabia  
Abdullah Altwarigi, Saudi Arabia  
Bassam Basuliman, Saudi Arabia  
Esam Murshid, Saudi Arabia  
Hulayel Alharbi, Saudi Arabia

**SPEAKERS** Michael Gnant, Austria  
Dario Trapani, Italy  
Alessandra Gennari, Italy  
Ana Bosch, Sweden  
Haider Abbas, Saudi Arabia

---

### LEARNING OBJECTIVES

- Understanding the biological rationale and clinical applications of CDK 4/6 inhibitors.
- Identify criteria for defining endocrine sensitivity and resistance using clinical and molecular parameters including ESMO guidelines.
- Discuss current best practices in first line therapy for HR positive HER2 negative MBC.
- Evaluate emerging biomarkers and to differentiate between the roles of tissue biopsy and liquid biopsy in advanced HR positive HER2 negative BC.
- Appraise the use of functional imaging tools in predicting response to endocrine therapy.
- Assess new endocrine treatment strategies.
- Integrate novel targeted therapies and develop approaches for managing adverse events.
- Examine strategies for continuing CDK 4/6 inhibition beyond disease progression.
- Understanding mechanisms underlying endocrine resistance.

---

### ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to [www.esmo.org](http://www.esmo.org).

## Saturday, 6 September 2025

---

- 09:00-09:10     **Welcome and introduction**  
Meteb Al-Foheidi, SA and Barbara Pistilli, FR
- 09:10-10:25     **Session 1 – CDK4/6 inhibitor and endocrine therapy in early and advanced Breast Cancer**  
Moderators: Ahmed Alwbari, SA  
Abdullah Altwarigi, SA
- 15'             Current endocrine therapies in EBC including CDK4/6 inhibitors  
Michael Gnant, AT
- 15'             Epidemiology and Current First-Line Therapies in HR+/HER2- Metastatic Breast Cancer in Saudi Arabia  
Meteb Al-Foheidi, SA
- 15'             How to define endocrine sensitivity and endocrine resistance in BC and ESMO Guidelines  
Alessandra Gennari, IT
- 30'             Discussion
- 10:25-10:55     Coffee break**
- 10:55-12:10     **Session 2 – Optimal biomarkers for patients stratification after CDK4/6 inhibitor in endocrine sensitive patients/tumors**  
Moderators: Ahmed Alshehri, SA  
Bassam Basuliman, SA
- 15'             Genomic and transcriptomic landscape of patients receiving CDK4/6 inhibitors  
Ana Bosch, SE
- 15'             Which biomarkers to use in HR+ HER2- advanced BC: liquid biopsy Vs. tissue biopsy  
Ana Bosch, SE
- 15'             Role of FES PET in predicting response to endocrine therapy  
Alessandra Gennari, IT
- 30'             Discussion
- 12:10-13:10     Lunch**
- 13:10-14:40     **Session 3 – Treatment strategies in endocrine sensitive MBC beyond progression on CDK4/6 inhibitors**  
Moderators: Esam Murshid, SA  
Hulayel Alharbi, SA

- 15' New SERDs and SERMs-based approaches  
Barbara Pistilli, FR
- 15' Targeted therapies: PI3K/AKT/mTOR inhibitors and PARP inhibitors  
Dario Trapani, IT
- 15' Maintaining CDK4/6 inhibition beyond progression  
Barbara Pistilli, FR
- 15' Management of adverse events of new endocrine and targeted therapies  
Dario Trapani, IT
- 30' Discussion
- 14:40-15:25 **Session 4 – Future perspectives**  
Moderators: Ahmed Alwbari, SA  
Abdullah Altwarigi, SA
- 15' New generation clinical trials in patients with endocrine-sensitive tumors  
Ana Bosch Campos, SE
- 15' Management of patient with endocrine-resistant tumors and future trials  
Barbara Pistilli, FR
- 15' Discussion
- 15:25-16:00 **Coffee break**
- 16:00-17:00 **Workshop Session**
- Workshop** **Molecular Tumour Board**  
Moderators: Esam Murshid, SA  
Bassam Basuliman, SA
- 30' Presentation of 3 cases by speaker and discussion  
30' Discussion
1. Case: 1<sup>st</sup> Endocrine resistant PIK3CA mutation –TBD
  2. Case: 2nd line ESR1 mutation –Haider Abbas, SA
  3. Case: gBRCA mutation – Barbara Pistilli, FR
- 17:00-17:15 **Synthesis and wrap-up**